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Background: Determination of a desirable diagnostic tests is an issue of im-
portance especially to differentiate between tuberculosis) TB(, sarcoidosis, and 
anthracosis. The purpose of the present study was to determine the differen-
tial diagnosis of tuberculosis, sarcoidosis and anthracosis with CD8, CD3, and 
CD4 by flow-cytometry. 
Materials and Methods: In this descriptive cross-sectional comparative sur-
vey, 40 consecutive patients attending to Masih Daneshvari Hospital in Tehran 
were enrolled and CD4/CD8 ratio, CD8, CD3, and CD4 were determined by 
flow-cytometry and compared across patients with three diseases including tu-
berculosis, sarcoidosis, and anthracosis.
Results: The results demonstrated that CD4 was significantly higher in anthra-
cosis cases (P<0.007) and the CD8 was significantly higher in patients with TB 
(P<0.008).
Conclusion: It was attained ultimately that CD4 and CD8 levels could be a 
desirable diagnostic markers for anthracosis and TB, respectively.
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In fact, the number of patients with TB has increased globally, 
as well as an increase in antibiotic resistance rates, which has 
also been reported in children [20,21]. In this regard, the pri-
mary step toward the initiation of treatment is to diagnose the 
bacteria appropriately; therefore, the clinicians can make the 
proper action and optimize the treatment process. Diagnostic 
markers, such as CD8, CD3, and CD4 are expected to be able 
to distinguish between these three diseases by flow cytometry. 
For this reason, mentioning the importance of reading and to 
reduce the dimensions of the case, in this study, the differen-
tial tuberculosis, sarcoidosis and anthracosis using diagnostic 
markers CD8, CD3, and CD4 could be analyzed by using flow 
cytometry.
MATERIALS and METHODS
In this observational descriptive cross-sectional study, 40 BAL 
(Broncho alveolar lavage) samples from patients suspected 
of having tuberculosis (n = 10), sarcoidosis (n = 20), and an-
thracosis (n = 10) who had been referred to Masih Daneshvari 
Hospital, evaluated and CD8, CD3, and CD4 determined by 
using flow cytometry and were compared in the three types of 
the disease. 
The inclusion criteria were the following: cases with tubercu-
losis, anthrax, and sarcoidosis; on the other hand, the exclusion 
criteria included a reluctance to continue the collaboration by 
the patient. In this study, the information was kept confidential 
and the participation in this research was voluntarily. Eventu-
ally, after gathering the required information from all subjects, 
we analyzed the data in which we used SPSS version 24 soft-
ware.
Statistical tests which were used in this context included chi-
square tests and analysis of variance (ANOVA) and the level of 
significance for the interpretation of the correlations between 
variables was 0.05.
RESULTS
According to the data, 20% in the tuberculosis group, 30% in 
the anthracosis group, and 50% in the sarcoidosis group were 
male (P>0.05). 
The mean age was significantly lower in patients with sarcoid-
osis than in other diseases (P=0.004), the mean age in the TB 
group was 56.7, in the anthracosis group was 62.1, and in the 
sarcoidosis group it was 47.5 years.
As shown in Table 1, the mean CD3 and CD4 / CD8 ratio did 
not indicate significant differences between the three groups 
(P>0.05) but the average CD4 significantly in anthracosis 
(P<0.007) and the mean of CD8 was significantly in the tuber-
culosis group (P<0.008) were higher than the other two groups. 
Distribution of diagnostic markers based on age and gender 
groups showed no significant difference (p>0.05).
INTRODUCTION
Sarcoidosis is a systemic disease characterized by the presence 
of non-caseating granulomas in affected organs, with the lung 
being the major diseased organ in more than 90% of patients 
[1,2].  Particularly, studies on BAL fluid in pulmonary sarcoid-
osis have demonstrated that sarcoid granuloma formation in the 
lung is preceded by an influx of mononuclear cells into the al-
veoli [1]. The presence of activated alveolar macrophages and 
CD4 (helper/inducer) T-lymphocytes were shown as markers 
of alveolitis [3,4].  Moreover, the increased numbers of BAL 
CD4  T cells are considered a hallmark of pulmonary sarcoid-
osis [5,6].  The percentages of CD4 and CD8 T-cells in BAL 
correlate properly with IHC methods in sarcoidosis patients 
[7]. Therefore, the BAL lymphocytosis, low or normal granulo-
cytes, and the increase in CD4/CD8 ratio appears in pulmonary 
sarcoidosis are not disease-specific and refined flow cytometric 
tests could be required to assist the diagnosis [8-10].
Apparently, the organs involved in the disease include the re-
spiratory system (In 90% of patients), visual system, and the 
immune system, which could be seen in patients in active phase 
[11]. It also causes high mortality in individuals who are partic-
ularly aged 55 years and older [12]. Therefore, the adoption of 
methods for early diagnosis and reduction of disease severity 
can play a significant role in reducing the burden of disease. 
Respiratory complications in patients with sarcoidosis could 
increase the respiratory tract allergens, particularly in allergens 
[13]. Anthracosis refers to pneumoconiosis due to coal dust and 
in the lung caused by the deposition of carbon particles, silica, 
quartz, etc. In the mucosa, submucosa and inside macrophages, 
which appear as black lesions in the bronchoscopy view 
[14,15]. The aforementioned patients are more prone to respi-
ratory infections, such as TB which the rates are 27% to 75% 
[16]. Therefore, adopting strategies for timely diagnosis and 
treatment and reducing the severity of the disease can be effec-
tive in reducing the burden of disease. Tuberculosis infection is 
caused by Mycobacterium tuberculosis. Among the most com-
mon infectious diseases, especially in countries, such as Iran. 
This organism could grow in different environments and thus 
the possibility of transferring it to others could be quite high. 
Eloquently, its prevalence varies from 3.7 to 9.6 % [17,18]. 
However, this incidence in different regions and in those with 
underlying diseases and conditions varies; moreover, the im-
portance of each area should be considered [11,12]. TB as a 
global emergency, requires assessment comprehensively. In ad-
dition to the failure of TB control programs in most developing 
countries, in recent years it has been attained that the treatment 
of TB is a multidimensional issue that includes complications, 
efficacy, compliance of patients, and drug resistance complica-
tions [17-19]. According to the above-mentioned methods, in 
order to reduce the proportion of TB is quite important in Iran. 
Table1. Distribution of diagnostic markers in three groups
CD4/CD8CD8CD4CD3
1 ±  0.825.1 ± 21.314.1± 11.939.2 ± 28.8TB
1.8 ± 1.721.8 ± 12.623.8± 13.129.7 ± 17.6Anthracosis
1.9 ± 1.58.5 ± 10.910.1 ± 8.213.4 ± 14.9Sarcoidosis
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DISCUSSION
We compared tuberculosis, sarcoidosis, and anthracosis by us-
ing diagnostic markers CD8, CD3, and CD4 analyzed by flow 
cytometry. The outcomes showed that the mean CD3 and CD4 
/ CD8 markers did not change significantly between the three 
groups. However, the CD4 mean was significantly higher in the 
anthracosis groups and the CD8 mean was significantly higher 
in TB groups.
In a study by Morteza et al. in Iran, the results were published 
in 2015, It was announced that CD8, CD4, CD56 can distin-
guish lung cancer from non-cancerous tissues. CD8 and CD4 
also could be useful in differentiating sarcoidosis. In addition, 
CD4 could be useful in differentiating tuberculosis [22]. How-
ever, in this study regarding TB, it is useful in differentiation 
of CD8 marker. A study was conducted as a cross-sectional an-
alytical study by Barcelos et al. in Brazil, and the results were 
published in 2006. By studying 20 patients with tuberculosis 
which was announced that CD19, CD4, and CD8 cell differ-
entiation and also predict response in treatment can be helpful 
for patients [23] which is similar to our research results. In a 
study, a review by Sweiss et al. in the United States, published 
in 2010. By studying 28 patients with sarcoidosis was indicated 
that CD19, CD4, and CD8 could be helpful in differentiating 
patients with severe sarcoidosis [24]. In fact, in the case of sar-
coidosis in our study was not quite helpful. In an observational 
study, as a cross-sectional analytical study, which was done by 
Kojima et al in Japan which the results published in 2012. By 
studying 38 patients with sarcoidosis the ration of CD4 to CD8 
was helpful in differentiating between patients with sarcoid-
osis [25]. However, there was no significant relationship in the 
mentioned study with our study. In a cross-sectional analytical 
study conducted by Rodrigues et al. In Brazil, the results were 
published in 2002. By studying 61 patients with suspected 
tuberculosis, it was indicated that CD38, CD4, and CD8 cell 
could be useful in differentiating patients with high detection 
efficiency is 90% [26]. Transparently, in our outcomes, CD8 
was the most effective for tuberculosis, which could be due to 
the greater involvement of cellular immunity.
Conclusion
In summary, the CD4 marker could be used to identify anthra-
cotic and CD8 markers for diagnosis of tuberculosis which they 
have a proper diagnostic performance. Therefore, for laborato-
ry diagnostic methods, they could be used to distinguish the 
two markers. Eventually, it is recommended that further studies 
be conducted to confirm the findings of this study with a higher 
sample size and multi-centered, and furthermore. Further stud-
ies on other diagnostic methods should be considered as well.
Indeed, it is suggested to plan effective methods to reduce the 
number of tuberculosis, anthracosis, and sarcoidosis in the 
community by identifying and reducing the effective factors 
in this field.
REFERENCES
1. R. P. Baughman, A. S. Teirstein, M. A. Judson, M. D. Ross-
man, H. Yeager Jr, E. A. Bresnitz, et al.Clinical charac-
teristics of patients in a case control study of sarcoidosis.
American journal of respiratory and critical care medi-
cine.2001;164(10):1885-89.
Nazanin Akbarifazli et al.
20 • School of Medicine Students‘ Journal (2019) 1:1
culture-positive M. tuberculosis or nontuberculous myco-
bacteria in South African gold miners.European Respirato-
ry Journal.2000;15(2):291-96.
17. L. A. Carson, L. Bland, L. Cusick, M. Favero, G. Bolan, A. 
Reingold, et al.Prevalence of nontuberculous mycobacte-
ria in water supplies of hemodialysis centers.Appl Environ 
Microbiol.1988;54(12):3122-25.
18. A.-L. Roux, E. Catherinot, F. Ripoll, N. Soismier, E. 
Macheras, S. Ravilly, et al.Multicenter study of preva-
lence of nontuberculous mycobacteria in patients with 
cystic fibrosis in France.Journal of clinical microbiolo-
gy.2009;47(12):4124-28.
19. K. S. Sachdeva, A. Kumar, P. Dewan, A. Kumar and S. Sa-
tyanarayana.New vision for Revised National Tuberculosis 
Control Programme (RNTCP): universal access-“reach-
ing the un-reached”.The Indian journal of medical re-
search.2012;135(5):690.
20. L. Nelson and C. Wells.Global epidemiology of childhood 
tuberculosis [Childhood TB].The International journal of Tu-
berculosis and lung Disease.2004;8(5):636-47.
21. D. Shingadia and V. Novelli.Diagnosis and treatment of 
tuberculosis in children.The Lancet infectious diseas-
es.2003;3(10):624-32.
22. E. Mortaz, H. Gudarzi, P. Tabarsi, I. M Adcock, M. R. Mas-
jedi, H. R. Jamaati, et al.Flow cytometry applications in the 
study of immunological lung disorders.Iranian Journal of 
Allergy, Asthma and Immunology.2015;14(1):12-18.
23. W. Barcelos, O. A. Martins‐Filho, T. M. P. D. Guimarães, M. 
H. P. Oliveira, S. Spíndola‐de‐Miranda, B. N. Carvalho, et 
al.Peripheral blood mononuclear cells immunophenotyping 
in pulmonary tuberculosis patients before and after treat-
ment.Microbiology and immunology.2006;50(8):597-605.
24. N. J. Sweiss, R. Salloum, S. Ghandi, M.-L. Alegre, R. 
Sawaqed, M. Badaracco, et al.Significant CD4, CD8, and 
CD19 lymphopenia in peripheral blood of sarcoidosis pa-
tients correlates with severe disease manifestations.PLoS 
One.2010;5(2):e9088.
25. K. Kojima, K. Maruyama, T. Inaba, K. Nagata, T. Yasuha-
ra, K. Yoneda, et al.The CD4/CD8 ratio in vitreous fluid 
is of high diagnostic value in sarcoidosis.Ophthalmolo-
gy.2012;119(11):2386-92.
26. D. d. S. d. S. Rodrigues, E. A. S. d. Medeiros, L. Y. Weckx, 
W. Bonnez, R. Salomão and E. G. Kallas.Immunopheno-
typic characterization of peripheral T lymphocytes in My-
cobacterium tuberculosis infection and disease.Clinical & 
Experimental Immunology.2002;128(1):149-54.
Dx of tuberculosis, sarcoidosis, and anthracosis by Flowcytometry
